Zynerba Pharmaceuticals (NASDAQ:ZYNE) issued its quarterly earnings results on Monday, March 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.60), Briefing.com reports. During the same period in the previous year, the company posted ($0.71) EPS.
Shares of ZYNE traded down $0.06 during midday trading on Thursday, hitting $9.13. 138,859 shares of the stock were exchanged, compared to its average volume of 329,969. Zynerba Pharmaceuticals has a 52-week low of $5.42 and a 52-week high of $25.95. The firm has a market cap of $123.54, a P/E ratio of -3.68 and a beta of 4.94.
A number of equities analysts have commented on ZYNE shares. Zacks Investment Research raised Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, December 8th. Cantor Fitzgerald set a $17.00 target price on Zynerba Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, January 3rd. Ladenburg Thalmann Financial Services initiated coverage on Zynerba Pharmaceuticals in a report on Monday, January 29th. They issued a “buy” rating and a $25.50 price target for the company. Oppenheimer reaffirmed a “hold” rating on shares of Zynerba Pharmaceuticals in a report on Wednesday, January 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price target on shares of Zynerba Pharmaceuticals in a report on Thursday, February 1st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $17.86.
Large investors have recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company purchased a new position in Zynerba Pharmaceuticals in the second quarter valued at $158,000. California State Teachers Retirement System purchased a new position in Zynerba Pharmaceuticals in the second quarter valued at $343,000. Finally, State Street Corp purchased a new position in Zynerba Pharmaceuticals in the second quarter valued at $2,698,000. Hedge funds and other institutional investors own 28.92% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was first published by BBNS and is the property of of BBNS. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://baseballnewssource.com/2018/04/05/zynerba-pharmaceuticals-zyne-issues-quarterly-earnings-results-meets-estimates/2028069.html.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.